DANAI DIMA, MD                                                          

Work Email: danaid@uw.edu

Personal Email: danaidima92@gmail.com

Education & Training

Hematology and Medical Oncology Fellowship

Cleveland Clinic Foundation, Cleveland, OH

July 2021 – June 2024

Internal Medicine Residency

Tufts University Medical Center, Boston, MA                                                                                        

June 2018 – June 2021

Doctor of Medicine, summa cum laude

National and Kapodistrian University of Athens, School of Health Sciences, Athens, GREECE

September 2010 – March 2017                                                                                                  

Clinical Licensures & Specialty Board Certifications

Licensures:

06/2018 – 06/2021 : MA State Medical License

06/2021 – present : OH State Medical License

5/2024 – present : WA State Medical License

Board Certification:

2021: American Board of Internal Medicine (ABIM)

Honors & Awards                         

2010 :   Eurobank Scholarship Award, for graduating 1^st from High School-Class Valedictorian

2012 :   Excellence in Physiology Student Award University of Athens, for demonstrating scholastic

excellence and significant academic achievement in Physiology.

2017 :   World Hellenic Biomedical Association (WHBA), Research Training Program in Clinical &  

             Experimental Medicine Scholarship Award

2017 :   Dean’s Honor List, Award of Academic Excellence, top 1% of class (ranked 3^rd in the

             class), University of Athens

2017 :   Hippocrates Graduation Award, “Summa Cum Laude’’, Athens Medical School

2020 :   Primary Care Hero, Tufts University Medical Center

2022 :   American Society of Hematology, Abstract Achievement Award

2023 :   American Society of Hematology, Abstract Achievement Award

Professional Societies                                                                                            

• American Medical Association (2018- present)

• American College of Physicians (2018- present)

• American Society of Clinical Oncology (2019- present)

• American Society of Hematology (2019- present)

• International Society on Thrombosis and Haemostasis (2021- present)

Teaching Activities & Leadership                                                                                                                          

During Residency Training at Tufts Medical Center, Boston MA

• Physical Diagnosis Course Instructor (2018-2021):

Led targeted bedside physical exam teaching sessions for small groups of 1^st and 2^nd year medical students.

• Group Discussion Leader (2019-2021):           

Facilitated small group sessions about physiology and pathophysiology in the fields of Rheumatology, Hematology, and Immunology for 2^nd-year medical students to improve academic performance.

• Facilitator for Medical Student Morning Report (2019-2021)

Lead 3^rd-year medical students through an in-depth patient presentation focusing on history and data interpretation and differential diagnosis.

• Mock Code Curriculum Committee Leader (2019-2021):

Designed, organized, and proctored high urgency clinical vignettes to educate resident and fellow physicians, nurses and clinical care technicians with the goal to enhance communication, performance and outcomes during medical emergencies on the inpatient hospital services.

During Fellowship Training at Cleveland Clinic Foundation, Cleveland OH

• Quality Improvement Fellow for Inpatient Hematology-Oncology Services (2021- present)

Review structure of impatient services, identify major problems, devise alternative models, present updates at staff meetings, disease group meetings, and annual performance evaluation meeting with the goal to improve overall patient care.

• Hematology-Oncology Fellowship Curriculum Committee Leader (2022- present)

Design the Hematology-Oncology fellows’ annual curriculum including core lectures, academic and other educational activities.

• VeloSano Grant Reviewer  (2022-present), Case Comprehensive Cancer Center

Scholar Activities

Abstracts

1. Basali D, Zureigat H, Nurse DP, Elmaleh H, Batah H, Adcock B, Wei W, Dima D, Valent J, Answer F, Samaras C, Khouri J, Williams L, Raza S, Heeckeren WJV, Mazzoni S. Efficacy of low-dose direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in newly diagnosed multiple myeloma. JCO. 2024;42(16_suppl):e19521-e19521. doi:10.1200/JCO.2024.42.16_suppl.e19521

2. Golmohammadi M, Albayyadhi M, Moradi A, Dima D, Sholehrasa H, Xu X, Mazzoni S, Raza S, and Jaberi-Douraki M. Comprehensive assessment of adverse event profiles associated with bispecific T cell engagers in multiple myeloma. JCO. 2024;42(16_suppl):e19527-e19527. doi:10.1200/JCO.2024.42.16_suppl.e19527

3. Zanwar S, Sidana S, Shune L, Castaneda Puglianini OA, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg PA, Sborov DW, Richard S, Khouri J, Lin Y, Patel KK, Kumar S, Hansen DK. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. JCO. 2024;42(16_suppl):7508-7508. doi:10.1200/JCO.2024.42.16_suppl.7508

4. Dima, D., Davis, J. A., Ahmed, N., Sannareddy, A., Shaikh, H., Mahmoudjafari, Z., Khouri, J., Kaur, G., Strouse, C., Valent, J., Anderson, L. D., Anwer, F., Abdallah, A.-O., & Hashmi, H. (2023). Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma. Blood, 142, 91. https://doi.org/10.1182/blood-2023-180421

5. Dima, D., Davis, J. A., Rashid, A., Rice, M., DeJarnette, S., Shune, L., Khouri, J., Raza, S., McGuirk, J. P., Anwer, F., Ahmed, N., Abdallah, A.-O., & Hashmi, H. (2023). Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease. Blood, 142, 4882. https://doi.org/10.1182/blood-2023-181331

6. Dima, D., Rashid, A., Davis, J. A., Awada, H., Abdallah, A.-O., Li, H., DeJarnette, S., Shune, L., Khouri, J., Hashmi, H., McGuirk, J. P., Anwer, F., & Ahmed, N. (2023). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study. Blood, 142, 4885. https://doi.org/10.1182/blood-2023-180368

7. Dima, D., Sannareddy, A., Ahmed, N., Davis, J. A., Shaikh, H., Mahmoudjafari, Z., Duco, M., Khouri, J., Kaur, G., Lochner, J., Anwer, F., Afrough, A., Valent, J., Hashmi, H., & Abdallah, A.-O. (2023). Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study. Blood, 142, 3330. https://doi.org/10.1182/blood-2023-180458

8. Dima, D., Ullah, F., Unlu, S., Basali, D., Khan, M., Khan, A. S., Jia, X., Jaberi-Douraki, M., Faiman, B. M., Mazzoni, S., Williams, L. S., Samaras, C. J., Valent, J., Anwer, F., Khouri, J., & Raza, S. (2023). Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12-Year Experience of a Large Academic Center. Blood, 142, 3407. https://doi.org/10.1182/blood-2023-181365

9. Ahmed, A., Dima, D., Row, K., Ullah, F., Awada, H., Basali, D., Kurish, H., Rice, M., Rudoni, J., Duco, M., Faiman, B. M., Khouri, J., Mazzoni, S., Williams, L. S., Raza, S., Samaras, C. J., Valent, J., & Anwer, F. (2023). Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution. Blood, 142(Supplement 1), 4724. https://doi.org/10.1182/blood-2023-182972

10. Davis, J. A., Dima, D., Ahmed, N., DeJarnette, S., McGuirk, J. P., Khouri, J., Valent, J., Anwer, F., Abdallah, A.-O., & Hashmi, H. (2023). Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma. Blood, 142, 3503. https://doi.org/10.1182/blood-2023-179981

11. Golmohammadi, M., Dima, D., Albayyadhi, M., Moradi, A., Raza, S., & Jaberi-Douraki, M. (2023). Pooled Analysis on Bispecific Antibody-Related Toxicities in Multiple Myeloma. Blood, 142, 1953. https://doi.org/10.1182/blood-2023-191305

12. Orland, M., Dima, D., Ullah, F., Awada, H., Basali, D., Faiman, B. M., Scott, C., Mazzoni, S., Williams, L. S., Samaras, C. J., Valent, J., Anwer, F., Raza, S., & Khouri, J. (2023). Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis. Blood, 142, 2031. https://doi.org/10.1182/blood-2023-183030

13. Ogbue, O., Unlu, S., Dima, D., Bravo-Perez, C., Williams, N. D., Ahmed, A., Veeraballi, S., Durmaz, A., Ullah, F., Gurnari, C., Visconte, V., & Maciejewski, J. P. (2023). Insights into Large Granular Lymphocytic Leukemia-Associated Hemolytic Anemia: Clinical Associations, Therapeutic Responses, and Optimal Management Strategies from a Large Institutional Study. Blood, 142, 5167. https://doi.org/10.1182/blood-2023-186071

14. Orland, M., Kubota, Y., Dima, D., Bravo-Perez, C., Guarnera, L., Gurnari, C., Maciejewski, J. P., & Visconte, V. (2023). Del(20q) As a Somatic Gene Rescue in Adult Patients: Can Germline Mutations Other Than SBDS be Found in Affected Patients? Blood, 142, 4095. https://doi.org/10.1182/blood-2023-191101

15. Ullah, F., Dima, D., Gurnari, C., Ahmed, A., Ogbue, O., Orland, M., Kawashima, N., Bravo-Perez, C., Unlu, S., Guarnera, L., Omar, N., Visconte, V., & Maciejewski, J. P. (2023). Outcomes of Antithymocyte Globulin and Cyclosporine for Severe Aplastic Anemia. Blood, 142, 5648. https://doi.org/10.1182/blood-2023-191264

16. Unlu, S., Haddad, C., Dima, D., Kewan, T., Ogbue, O., Bahaj, W., Bravo-Perez, C., Guarnera, L., Kubota, Y., Carraway, H. E., Gurnari, C., Corey, S. J., Mehta, H. M., Visconte, V., & Maciejewski, J. P. (2023). Somatic Genetic Rescue Involving CSF3R and Other Novel Phosphothyrosine Kinase Receptor Mutations Occurring in Myeloid Malignancies. Blood, 142, 3219. https://doi.org/10.1182/blood-2023-187151

17. Atallah, R., Saif, M. S. I., Dima, D., Shrestha, A., Anwer, F., Mushtaq, M. U., Lutfi, F., Shune, L., Hashmi, H., Ganguly, S., McGuirk, J. P., Atrash, S., Abdallah, A.-O., Banerjee, R., & Ahmed, N. (2023). Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians. Blood, 142, 6678. https://doi.org/10.1182/blood-2023-181218

18. Awada, H., Hajj Ali, A., Dima, D., Sauter, C. S., Williams, L., Khouri, J., Raza, S., Mazzoni, S., Valent, J., Samaras, C. J., & Anwer, F. (2023). Impact of Prior Lines of Therapy before Autologous Hematopoietic Cell Transplant on Survival in Standard Risk Multiple Myeloma. Blood, 142, 7069. https://doi.org/10.1182/blood-2023-189995

19. Awada, H., Kubota, Y., Gurnari, C., Bravo-Perez, C., Unlu, S., Guarnera, L., Dima, D., Durmaz, A., Awada, H., Maciejewski, J. P., & Visconte, V. (2023). Lessons of Nature in Trisomy-8 MDS and AML: Determinants of Clonal Drive. Blood, 142, 5707. https://doi.org/10.1182/blood-2023-190773

20. Bravo-Perez, C., Gurnari, C., Kawashima, N., Dima, D., Ogbue, O., Guarnera, L., Kubota, Y., Williams, N. D., Ahmed, A., Ullah, F., Durmaz, A., Nakashima, M., Visconte, V., & Maciejewski, J. P. (2023). LGL in MGUS or MGUS in LGL? Lessons of Nature and Their Clinical Implications. Blood, 142(Supplement 1), 4769. https://doi.org/10.1182/blood-2023-181975

21. Durmaz, A., Gurnari, C., Pagliuca, S., Hercus, C., Bravo-Perez, C., Guarnera, L., Williams, N. D., Dima, D., Nautiyal, I., Kubota, Y., Kawashima, N., Scott, J., Visconte, V., & Maciejewski, J. P. (2023). Reverse Engineering of Antigenic Peptides in LGL to Decipher Disease Triggers. Blood, 142, 246. https://doi.org/10.1182/blood-2023-190381

22. Jaberi-Douraki, M., Xu, X., Ramachandran, R. A., Faiman, B., Anwer, F., Samaras, C., Riviere, J., Gedara, N. I. M., Golmohammadi, M., Shaikh, H., Shune, L., Masood, A., Mazzoni, S., Williams, L., Zhao, J., Valent, J., Dima, D., Abbas, A., Cossor, F., … Raza, S. (2023). P-465 Global disparities in multiple myeloma: Examining adverse events and drug toxicity trends. Clinical Lymphoma, Myeloma and Leukemia, 23, S295–S296. https://doi.org/10.1016/S2152-2650(23)02082-7

23. Kaplan, D., Christian, E., Valent, J., Anwer, F., Raza, S., Mazzoni, S., Samaras, C. J., Williams, L. S., Dima, D., Shepherd, K., Fennema, J., Fada, S., Nakashima, M., Hanna, M., Lazarus, H. M., & Khouri, J. (2023). Molecular Expression Differences in Blood Mononuclear Cells in Patients with AL Amyloidosis. Blood, 142, 5031. https://doi.org/10.1182/blood-2023-180735

24. Lin, J., Emhoff, K., Maqbool, M., Irons, E., Alban, T., Dima, D., Chang, M.-H., Dai, E., Hong, H., Maeda, R., Jeon, J., Williams, L., Yu, J., Chan, T., Lathia, J., Anwer, F., Valent, J., Jung, J., & Zhao, J. (2023). P-222 Development of pERp1-ADC as a novel therapeutic for multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 23, S157–S158. https://doi.org/10.1016/S2152-2650(23)01840-2

25. Mansour, R., Davis, J. A., Minchak, M., Atallah, R., Saif, M. S. I., Logan, E., Tabak, C., Rashid, A., Dima, D., Ahmed, N., Abdallah, A.-O., & Hashmi, H. (2023). Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Daratumumab-Naïve Relapsed Multiple Myeloma: Multicenter Real-World Experience. Blood, 142, 3361. https://doi.org/10.1182/blood-2023-179661

26. Midha, S., Gurumurthi, A., Costello, P., Redd, R. A., Freeman, C. L. L., Castaneda, O., Gonzalez, R., Ionescu, F., Gaballa, M., Kalariya, N., Khouri, J., Dima, D., Kocoglu, M. H., Sborov, D., Wagner, C. B., Atrash, S., Voorhees, P. M., Hashmi, H., Davis, J. A., … Patel, K. K. (2023). Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma. Blood, 142, 3499. https://doi.org/10.1182/blood-2023-187565

27. Raza, S., Xu, X., Zhang, J., Ramachandran, R. A., Faiman, B., Anwer, F., Samaras, C., Riviere, J., Gedara, N. I. M., Golmohammadi, M., Williams, L., Khouri, J., Mazzoni, S., Masood, A., Zhao, J., Dima, D., Abbas, A., Shune, L., Valent, J., & Jaberi-Douraki, M. (2023). P-366 Signaling pathway data analytics of nephropathy and neuropathy from drug toxicities in multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 23, S241. https://doi.org/10.1016/S2152-2650(23)01984-5

28. Wagner, C. B., Sweiss, K., Anto, E., Gonzalez, R., Castaneda Puglianini, O. A., Freeman, C. L. L., Ionescu, F., Patel, K. K., Ferreri, C., Gaballa, M., Shune, L., McGuirk, J. P., Sidana, S., Hovanky, V., Khouri, J., Dima, D., Hashmi, H., Davis, J. A., Afrough, A., … Kocoglu, M. H. (2023). Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium. Blood, 142, 4880. https://doi.org/10.1182/blood-2023-187440

29. Williams, L. S., Khosravi, B., Velimirovic, M., Khouri, J., Raza, S., Mazzoni, S., Samaras, C. J., Awada, H., Dima, D., Valent, J., & Anwer, F. (2023). An Ensemble Machine Learning Model Using Gradient Boosting Identifies Patients with Disease Progression in Newly Diagnosed Multiple Myeloma. Blood, 142, 1990. https://doi.org/10.1182/blood-2023-188762

30. Xu, X., Raza, S., Zhang, J., Ramachandran, R. A., Faiman, B., Anwer, F., Samaras, C., Riviere, J., Gedara, N. I. M., Golmohammadi, M., Williams, L., Khouri, J., Mazzoni, S., Masood, A., Zhao, J., Dima, D., Abbas, A., Shune, L., Valent, J., & Jaberi-Douraki, M. (2023). P-375 Unraveling signaling pathways in multiple myeloma cardiovascular toxicities from pharmacovigilance and pharmacogenomics data mining. Clinical Lymphoma, Myeloma and Leukemia, 23, S246–S247. https://doi.org/10.1016/S2152-2650(23)01993-6

31. Afrough, A., Hashmi, H., Hansen, D.K., Sidana, S., Ahn, C., Dima, D., Freeman, C.L., Castaneda Puglianini O.A., Kocoglu, M.H., Atrash, S., Voorhees, P.M., Shune, L., Simmons, G., Sborov, D.W., Ferreri C.J., Burton Wagner, C., Patel, K.K., Khouri, J., Anderson,  L.D., Jr, Lin, Y. Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium Journal of Clinical Oncology 2023 41:16_suppl, 8013-8013

32. Mishra, R., Dima, D., Durmaz, A., Mian, A., Mukherjee, S., Caimi, P.F., Jagadeesh, D. A population-level analysis of survival in patients with ALK+ anaplastic large cell lymphoma (ALCL) in the era of novel therapies. Journal of Clinical Oncology 2023 41:16_suppl, e18863-e18863

33. Sidana, S., Peres, L., Hashmi, H., Hosoya, H., Ferreri, C., Atrash, S., Khouri, J., Voorhees, P.M., Dima, D., Simmons, G.L., Kalariya, N., Hovanky, V., Bharadwaj, S., Arai, S., Miklos, D.B., Wagner, C., Davis, J.A., Sborov, D.W., Nishihori, T., Alsina, M., Locke, F.L., Gonzalez, R., Kocoglu, M.H., Sannareddy, A., Afrough, A., McGuirk, J.P., Shune, L., Patel, K.K., Hansen, D.K., 2023. Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience. Presented at the 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Tandem Meetings.

34. Dima, D., Hasipek, M., Singh, D.J., Jiang, D., Tiwari, A.D., Grabowski, D., Parker, Y., Lindner, D.J., Zhao, J., Shain, K.H., Khouri, J., Maciejewski, J.P., Jha, B.K. Heightened Endoplasmic-Reticulum Stress Is a Targetable Vulnerability of Malignant Plasma Cells in Multiple Myeloma. Blood 140, 7100–7101. (2022)

35. Dima, D., Ullah, F., Omar, N., Gurnari, C., Dhillon, P., Visconte, V., Jha, B.K., Maciejewski, J.P. Clinical and Mechanistic Relationship of T-Cell Large Granular Lymphocytic Leukemia (TLGL) and monoclonal Gammopathy of Undetermined Significance (MGUS). Blood 140, 9402–9403. (2022)

36. Dima, D., Li, A., Granat, L.M., Dhillon, P., Gurnari, C., Yalamanchali, A., Mirzai, S., Wei, W., Faiman, B.M., Williams, L.S., Mazzoni, S., Samaras, C.J., Anwer, F., Valent, J., Khouri, J. External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs. Blood 140, 11299–11300. (2022)

37. Ullah, F., Dima, D., Gurnari, C., Balasubramanian, S.K., Ogbue, O., Awada, H., Kawashima, N., Omar, N., Thota, S., Carraway, H.E., Visconte, V., Maciejewski, J.P. Intense Immunosuppressive Therapy (anti-thymocyte globulin, alemtuzumab) As Salvage Therapy in Refractory T-Cell Large Granular Lymphocytic Leukemia and Pure Red Cell Aplasia. Blood 140, 5795–5796. (2022)

38. Gurnari, C., Awada, H., Aly, M., Dima, D., Ullah, F., Kawashima, N., Kubota, Y., Colak, C., Visconte, V., Pagliuca, S., Patel, B.J., Bat, T., Maciejewski, J.P. Clinico-Molecular Risk Factors and Management of Thrombosis in a Large Real-Life Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria in the New Era of Anti-Complement Inhibitors and Doacs. Blood 140, 8513–8514. (2022)

39. Gurnari, C., Durmaz, A., Kubota, Y., Aly, M., Ogbue, O., Ullah, F., Dima, D., Awada, H., Kawashima, N., LaFramboise, T., Padgett, R.A., Haferlach, T., Maciejewski, J.P., Visconte, V. Dead and Deah-Box Helicases Other Than DDX41 Are Mutated in Myeloid Neoplasia. Blood 140, 9747–9748. (2022)

40. Gurnari, C., Gagelmann, N., Badbaran, A., Awada, H., Dima, D., Pagliuca, S., d’Aveni, M., Attardi, E., Cerretti, R., Christine, W., Rubio, M.T., Maciejewski, J.P., Kröger, N. Allogeneic Stem Cell Transplant for Myelodysplastic Syndrome in the New Molecular Era of IPSS-M. Blood 140, 10616–10617. (2022)

41. Awada, Hussein, Durmaz, A., Kewan, T., Ullah, F., Dima, D., Awada, Hassan, Pagliuca, S., Meggendorfer, M., Haferlach, T., Gurnari, C., Visconte, V., Maciejewski, J.P. Trisomy-6: The Ying and Yang of Chromosome 6 Aberrations. Blood 140, 8648–8649. (2022)

42. Awada, H., Hajj Ali, A., Dima, D., Granat, L.M., Sheu, M., Dhillon, P., Rice, M., Kurish, H.P., Williams, L.S., Anwer, F., Khouri, J. Validation of the CIBMTR Scoring System in Predicting Early Relapse of Multiple Myeloma Post Autologous Hematopoietic Cell Transplant. Blood 140, 7217–7218. (2022)

43. Awada, H., Hajj Ali, A., Dima, D., Granat, L.M., Sheu, M., Dhillon, P., Rice, M., Kurish, H.P., Williams, L.S., Anwer, F., Khouri, J. Validation of the Gatmo Score in Predicting Mortality Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients. Blood 140, 10583–10584. (2022)

44. Jiang, D., Pan, F., Guan, Y., Gu, X., Kawashima, N., Singh, D.J., Dima, D., Qu, G., Greenberg, E.F., Visconte, V., Mian, O., Xu, M., Maciejewski, J.P., Jha, B.K. Demonstration That Loss of TET2 Impairs DNA Mismatch Repair Resulting in Clonally Restricted Genomic Instability. Blood 140, 1989–1990. (2022)

45. Peres, L.C., Oswald, L.B., Dillard, C., De Avila, G., Nishihori, T., Blue, B.J., Freeman, C.L., Locke, F.L., Alsina, M., Castaneda Puglianini, O.A., Shune, L.O., Sborov, D.W., Wagner, C.B., Dima, D., Hashmi, H., Davis, J., Kocoglu, M.H., Atrash, S., Simmons, G., Kalariya, N., Ferreri, C.J., Sannareddy, A., Afrough, A., Voorhees, P.M., Khouri, J., McGuirk, J.P., Sidana, S., Hansen, D.K., Patel, K. Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy. Blood 140, 623–625. (2022)

46. Sidana, S., Peres, L.C., Hashmi, H., Hosoya, H., Ferreri, C.J., Atrash, S., Khouri, J., Voorhees, P.M., Dima, D., Simmons, G., Kalariya, N., Hovanky, V., Bharadwaj, S., Arai, S., Miklos, D.B., Wagner, C.B., Davis, J., Sborov, D.W., Nishihori, T., Alsina, M., Locke, F.L., Gonzalez, R., Kocoglu, M.H., Sannareddy, A., Afrough, A., McGuirk, J.P., Shune, L.O., Patel, K., Hansen, D.K. Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience. Blood 140, 10377–10379. (2022)

47. Ferreri, C.J., Hildebrandt, M.A.T., Hashmi, H., Shune, L.O., McGuirk, J.P., Sborov, D.W., Wagner, C.B., Kocoglu, M.H., Atrash, S., Voorhees, P.M., Khouri, J., Dima, D., Afrough, A., Sannareddy, A., Simmons, G., Davis, J., Kalariya, N., Peres, L.C., Alsina, M., Locke, F.L., Sidana, S., Hansen, D.K., Patel, K., Castaneda Puglianini, O.A. Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience. Blood 140, 1856–1858. (2022)

48. Hashmi, H., Hansen, D.K., Peres, L.C., Castaneda Puglianini, O.A., Freeman, C.L., De Avila, G., Sidana, S., Shune, L.O., Sborov, D.W., Davis, J., Wagner, C.B., Kocoglu, M.H., Atrash, S., Voorhees, P.M., Simmons, G., Ferreri, C.J., Kalariya, N., Sannareddy, A., Dima, D., Khouri, J., McGuirk, J.P., Locke, F.L., Baz, R.C., Patel, K., Alsina, M. Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience. Blood 140, 4642–4645. (2022)

49. Khouri, J., Li, H., Hansen, D.K., Sidana, S., Shune, L.O., DeJarnette, S., Anwer, F., Sborov, D.W., Wagner, C.B., Kocoglu, M.H., Atrash, S., Voorhees, P.M., Valent, J., Peres, L.C., Hovanky, V., Simmons, G., Dima, D., Kalariya, N., Afrough, A., Kaur, G., Sannareddy, A., Ferreri, C.J., Davis, J., McGuirk, J.P., Locke, F.L., Baz, R.C., Hamilton, B.K., Alsina, M., Sauter, C.S., Hashmi, H., Patel, K. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience. Blood 140, 10427–10429. (2022)

50. Zarif, T.E., Nassar, A., Adib, E., Fitzgerald, B., Huang, J., Mouhieddine, T., Nonato, T., McKay, R., Li, M., Mittra, A., Owen, D., Lorentsen, M., Dittus, C., Dizman, N., Emu, B., Falohun, A., Abdel-Wahab, N., Bankapur, A., Reed, A., Dobbs, R., Kim, C., Arora, A., Shah, N., El-Am, E., Kozaily, E., Abdallah, W., Al-Hader, A., Ghazal, B.A., Saeed, A., Drolen, C., Lechner, M., Espinar, J., Nebhan, C., Johnson, D., Haykal, T., Morse, M., Cortellini, A., Pinato, D., Pria, A.D., Bower, M., Hall, E., Bakalov, V., Bahary, N., Rajkumar, A., Mangla, A., Shah, V., Singh, P., Nana, F.A., Lia, N.L., Dima, D., Funchain, P., Saleem, R., Woodford, R., Ao, G.L., Menzies, A., Genova, C., Barletta, G., Puri, S., Florou, V., Idossa, D., Queirolo, P., Lamberti, G., Addeo, A., Bersanelli, M., Freeman, D., Xie, W., Ramaswami, R., Marron, T., Choueiri, T., Lurain, K., Baden, L., Sonpavde, G., Naqash, A.R. 437 Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium. J Immunother Cancer 10. (2022)

51. D Dima, F Chamseddine, P Dhillon, H Shah, B Osantowski, O Ogbue, et al. P-134: Clinical characteristics and long-term outcomes of patients with POEMS syndrome: a large academic center’s experience. Clinical Lymphoma, Myeloma and Leukemia 22, S108-S109, 2022

52. D Dima, N Lopetegui-Lia, O Ogbue, B Osantowski, R Ahmed, D Basali, et al. Immunotherapy versus targeted therapy in the adjuvant setting for resected stage III melanoma: A single institution study. Journal of Clinical Oncology 40 (16_suppl), e21578-e21578, 2022

53. N Lopetegui-Lia, D Dima, B Osantowski, R Davis, JM Song, et al. Bevacizumab for radiation necrosis of the brain or steroid-refractory edema in patients with melanoma receiving immune checkpoint inhibitors. Journal of Clinical Oncology 40 (16_suppl), e14008-e14008, 2022

54. R Ahmed, M Sheu, W Wei, MC Ornstein, TD Gilligan, D Dima, S Campbell. Prognostic factors and clinical outcomes in patients with upper tract urothelial carcinoma undergoing surgery: The Cleveland Clinic experience. Journal of Clinical Oncology 40 (16_suppl), 4593-4593, 2022

55. Lopetegui N, Dima D, Buchberger DS, Roof L, Lorenz RR, Prendes B, et al. Immunotherapy Response in Cutaneous Squamous Cell Carcinoma Patients with Cranial Nerve Involvement. International Journal of Radiation Oncology*Biology*Physics. 2022 Apr 1;112(5):e38–9

56. Zhang, D., Dima, D., Lalla, M., Toskic, D., Zhou, P., Godara, A., Comenzo, R.L. The Pattern of Organ Responses Varies in Patients with Systemic Light-Chain Amyloidosis and Heart or Kidney or Heart and Kidney Involvement Who Achieve Deep Hematologic Responses. Blood 138, 2715. (2021)

57. Niyoti Reddy, Danai Dima, Danica Maria Vodopivec Kuri, David McAneny, Matthew Kulke, Stephanie L Lee. Use Of Temozolomide In Parathyroid Carcinoma With Negative Mgmt Promoter Methylation. Journal of the Endocrine Society, Volume 5, Issue Supplement_1, April-May 2021, Page A1008

58. Dima, D., Hu, X., Dower, D., Comenzo, R.L., Varga, C. Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience.  Blood 136, 44-45 (2020)

59. Dima, D., Hu, X., Dower, J., Comenzo, R.L., Varga, C. Pattern of Use and Outcomes of Daratumumab Therapy in Patients with Multiple Myeloma in a Real-World Setting: A Single Institution Experience. Blood 136, 16-17 (2020)

60. Hachem, H., Levitz, D., Dima, D., Dower, J., Fresco, R. B., Weidner, R.A., Buchsbaum, R. J., Erban, J. K., Parsons, S. K. Contemporary use of inpatient antineoplastic (IP) treatment (Rx): Who is getting care and why? Journal of Clinical Oncology 2019 37:15_suppl, e18015-e18015

Peer-Reviewed Publications

1. Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, Anwer F, Sborov D, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Peres L, Hovanky V, Simmons G, Williams L, Raza S, Afrough A, Anderson LD Jr, Ferreri C, Hashmi H, Davis J, McGuirk J, Goldsmith S, Borogovac A, Lin Y, Midha S, Nadeem O, Locke FL, Baz R, Hamilton B, Alsina M, Sauter C, Patel K, Kaur G. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience. Transplant Cell Ther. 2024 Aug;30(8):790.e1-790.e16. doi: 10.1016/j.jtct.2024.05.025.

2. Gordon J, Bravo-Perez C, Guarnera L, Unlu S, Kawashima N, Ahmed A, Haddad C, Kubota Y, Nautiyal I, Ullah F, Dima D, Williams ND, Kewan T, Bahaj W, Carraway HE, Yang CY, Gurnari C, Visconte V, Maciejewski JP. Non-canonical FLT3 alterations reveal novel germline FLT3 variants leading to somatic gene rescue mutations. Blood Cancer J. 2024 Jul 30;14(1):125. doi: 10.1038/s41408-024-01104-9.

3. Dima D, Hughes M, Orland M, Ullah F, Goel U, Anwer F, Raza S, Mazzoni S, Bhutani D, Williams L, Lentzsch S, Samaras C, Valent J, Chakraborty R, Khouri J. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy. Amyloid. 2024 Sep;31(3):195-201. doi: 10.1080/13506129.2024.2366806.

4. Dima D, Goel U, Sannareddy A, Ibeh N, Ullah F, Afrough A, Mazzoni S, Mehdi A, Rudoni J, Raza S, De Simone N, Williams L, Khan A, Rashid A, Rice M, Ricci K, Samaras C, Valent J, Anderson LD, Anwer F, Kaur G, Khouri J. Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy. Hematol Oncol. 2024 Jul;42(4):e3293. doi: 10.1002/hon.3293.

5. Wesson W, Dima D, Suleman N, Saif MSI, Tabak C, Logan E, Davis JA, McGann M, Furqan F, Mohan M, Rashid A, Abdallah AO, Ullah F, Shune L, Mushtaq MU, Raza S, McGuirk J, Hamadani M, Anwer F, Hashmi H, Ahmed N. Timing of Toxicities and Non-relapse Mortality Following CAR T Therapy in Myeloma. Transplant Cell Ther. 2024 Jun 11:S2666-6367(24)00469-X. doi: 10.1016/j.jtct.2024.06.012.

6. Lin CH, Tariq MJ, Ullah F, Sannareddy A, Khalid F, Abbas H, Bader A, Samaras C, Valent J, Khouri J, Anwer F, Raza S, Dima D. Current Novel Targeted Therapeutic Strategies in Multiple Myeloma. Int J Mol Sci. 2024 Jun 4;25(11):6192. doi: 10.3390/ijms25116192.

7. Dima D, Abdallah AO, Davis JA, Awada H, Goel U, Rashid A, DeJarnette S, Anwer F, Shune L, Raza S, Mahmoudjafari Z, Williams L, Faiman B, McGuirk JP, Sauter CS, Ahmed N, Khouri J, Hashmi H. Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy. Blood Cancer J. 2024 May 31;14(1):90. doi: 10.1038/s41408-024-01068-w.

8. Dima D, Lopetegui‐Lia N, Ogbue O, Osantowski B, Ullah F, Jia X, Song JM, Gastman B, Isaacs J, Kennedy LB, Funchain P. Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies. Cancer Med. 2024 Jun 20;13(12):e7257. doi: 10.1002/cam4.7257.

9. Awada H, Durmaz A, Kewan T, Ullah F, Dima D, Awada H, Pagliuca S, Meggendorfer M, Haferlach T, Gurnari C, Visconte V, Maciejewski JP. Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis. Leukemia. 2024 Jun;38(6):1411-1414. doi: 10.1038/s41375-024-02268-w.

10. Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD Jr, Lin Y. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024 Apr 12;14(1):63. doi: 10.1038/s41408-024-00993-0.

11. Dima D, Khouri J. The role of therapeutic plasma exchange in plasma cell disorders. Ann Hematol. 2024 Apr 1. doi: 10.1007/s00277-024-05712-0.

12. Dima D, Sauter CS. Biological Age is No Barrier for Adult Patients Undergoing CAR T for Non-Hodgkin's Lymphoma or Multiple Myeloma. Transplant Cell Ther. 2024 May;30(5):462-464. doi: 10.1016/j.jtct.2024.04.002.

13. Habib MH, Tiger YKR, Dima D, Schlögl M, McDonald A, Mazzoni S, Khouri J, Williams L, Anwer F, Raza S. Role of Palliative Care in the Supportive Management of AL Amyloidosis-A Review. J Clin Med. 2024 Mar 29;13(7):1991. doi: 10.3390/jcm13071991.

14. Ullah F, Markouli M, Orland M, Ogbue O, Dima D, Omar N, Mustafa Ali MK. Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and Treatment. Cancers (Basel). 2024 Mar 27;16(7):1307. doi: 10.3390/cancers16071307.

15. Gurnari C, Awada H, Pagliuca S, Dima D, Ullah F, Kawashima N, Kubota Y, Colak C, Visconte V, Patel BJ, Dhillon V, Marneni N, Balasubramanian SK, Kishtagari A, Bat T, Maciejewski JP. Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043 patient/years analysis. Blood. 2024 Mar 21:blood.2024023988. doi: 10.1182/blood.2024023988.

16. Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldés A, Stölzel F, Rathje K, Fischer L, Born P, Schäfer L, Albici AM, Schub N, Kfir-Erenfeld S, Assayag M, Asherie N, Wulf GG, Kharboutli S, Müller F, Shune L, Davis JA, Anwer F, Vucinic V, Platzbecker U, Ayuk F, Kröger N, Khouri J, Gurnari C, McGuirk J, Stepensky P, Abdallah AO, Fernández de Larrea C. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2024 Feb 15:JCO2302232. doi: 10.1200/JCO.23.02232.

17. Dima D, Mansour R, Davis JA, Minchak M, Goel U, Atallah R, Logan E, Tabak C, Rashid A, Ahmed N, Abdallah AO, Hashmi H. Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma. Eur J Haematol. 2024 Feb 21. doi: 10.1111/ejh.14193.

18. Dima D, Rashid A, Davis JA, Shune L, Abdallah AO, Li H, DeJarnette S, Khouri J, Williams L, Hashmi H, Raza S, McGuirk J, Anwer F, Ahmed N. Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study. Br J Haematol. 2024 Jan 23. doi: 10.1111/bjh.19302.

19. Dima D, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H, Shune L, Kaur G, Khouri J, Afrough A, Strouse C, Lochner J, Mahmoudjafari Z, Raza S, Valent J, Anderson LD Jr, Anwer F, Abdallah AO, Hashmi H. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience. Transplant Cell Ther. 2023 Dec 26:S2666-6367(23)01752-9. doi: 10.1016/j.jtct.2023.12.016.

20. Davis JA, Dima D, Ahmed N, DeJarnette S, McGuirk J, Jia X, Raza S, Khouri J, Valent J, Anwer F, Abdallah AO, Hashmi H. Impact of Frailty on Outcomes After CAR T-cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma. Transplant Cell Ther. 2023 Dec 22:S2666-6367(23)01750-5. doi: 10.1016/j.jtct.2023.12.015

21. Ogbue OD, Bahaj W, Kewan T, Ahmed R, Dima D, Willimas N, Durmaz A, Visconte V, Maskal SM, Gurnari C, Steven R, Maciejewski JP. Splenectomy outcomes in immune cytopenias: Treatment outcomes and determinants of response. J Intern Med. 2023 Nov 13. doi: 10.1111/joim.13742.

22. Dima D, Orland M, Ullah F, Anwer F, Mazzoni S, Raza S, Chaulagain CP, Samaras C, Valent J, Williams L, Khouri J. Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 Aug 1:S2152-2650(23)00226-4. doi: 10.1016/j.clml.2023.07.007.

23. Dima D, Valent J, Khouri J. Daratumumab monotherapy for relapsed POEMS syndrome. Am J Hematol. 2023 Aug 7. doi: 10.1002/ajh.27050.

24. Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini OA, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri CJ, Anderson LD Jr, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees PM, Khouri J, McGuirk JP, Sidana S, Hansen DK, Patel KK. Racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T-cell therapy. Blood Adv. 2023 Oct 16:bloodadvances.2023010894. doi: 10.1182/bloodadvances.2023010894.

25. Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, Dima D, Atrash S, Voorhees P, Simmons G, Sborov DW, Kalariya N, Hovanky V, Bharadwaj S, Miklos D, Wagner C, Kocoglu MH, Kaur G, Davis JA, Midha S, Janakiram M, Freeman C, Alsina M, Locke F, Gonzalez R, Lin Y, McGuirk J, Afrough A, Shune L, Patel KK, Hansen DK. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283940

26. Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD Jr, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023 Aug 9;13(1):117. doi: 10.1038/s41408-023-00886-8.

27. Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD Jr, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience. Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.283888

28. El Zarif T, Nassar AH, Adib E, Fitzgerald BG, Huang J, Mouhieddine TH, Rubinstein PG, Nonato T, McKay RR, Li M, Mittra A, Owen DH, Baiocchi RA, Lorentsen M, Dittus C, Dizman N, Falohun A, Abdel-Wahab N, Diab A, Bankapur A, Reed A, Kim C, Arora A, Shah NJ, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Abu Ghazal B, Saeed A, Drolen C, Lechner MG, Drakaki A, Baena J, Nebhan CA, Haykal T, Morse MA, Cortellini A, Pinato DJ, Dalla Pria A, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Aboubakar Nana F, Lopetegui-Lia N, Dima D, Dobbs RW, Funchain P, Saleem R, Woodford R, Long GV, Menzies AM, Genova C, Barletta G, Puri S, Florou V, Idossa D, Saponara M, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Reid EG, Chiao EY, Sharon E, Johnson DB, Ramaswami R, Bower M, Emu B, Marron TU, Choueiri TK, Baden LR, Lurain K, Sonpavde GP, Naqash AR. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. J Clin Oncol. 2023 May 16:JCO2202459. doi: 10.1200/JCO.22.02459.

29. Markouli M, Ullah F, Unlu S, Omar N, Lopetegui-Lia N, Duco M, Anwer F, Raza S, Dima D. Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management. Curr Oncol. 2023 Jul 1;30(7):6330-6352. doi: 10.3390/curroncol30070467.

30. Ullah F, Pillai AB, Omar N, Dima D, Harichand S. Early-Onset Colorectal Cancer: Current Insights. Cancers (Basel). 2023 Jun 15;15(12):3202. doi:10.3390/cancers15123202

31. Mishra R, Dima D, Kumar SA, Mian A, Taneja A, Karna R, Caimi PF, Hill BT, Dean R, Jagadeesh D. A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies. Hematol Oncol. 2023 Jun 13. doi: 10.1002/hon.3192.

32. Dima D, Ullah F, Mazzoni S, Williams L, Faiman B, Kurkowski A, Chaulagain C, Raza S, Samaras C, Valent J, Khouri J, Anwer F. Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice. Cancers (Basel). 2023 Apr 5;15(7):2160. doi: 10.3390/cancers15072160.

33. Hubben A, Dima D, Atieh T, Chaulagain C, Faiman B, Ferraro C, Mazzoni S, Williams L, Samaras C, Valent J, Sauter C, Anwer F, Khouri J. On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone. Bone Marrow Transplant. 2023 Feb 24. doi: 10.1038/s41409-023-01938-0.

34. Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol. 2023 Jan 9:JCO2201365. doi: 10.1200/JCO.22.01365.

35. Dima D, Mazzoni S, Anwer F, Khouri J, Samaras C, Valent J, Williams L. Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of Therapeutic Innovation. JCO Oncol Pract. 2023 Feb 28:OP2200396. doi: 10.1200/OP.22.00396.

36. Dima D, Li A, Granat LM, Dhillon P, Chamseddine F, Yalamanchali A, Mirzai S, Wei W, Samaras CJ, Valent J, Anwer F, Khouri J. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs. Br J Haematol. 2023 Jan 5. doi: 10.1111/bjh.18630.

37. Farha N, Dima D, Ullah F, Kamath S. Precision Oncology Targets in Biliary Tract Cancer. Cancers (Basel). 2023 Mar 31;15(7):2105. doi: 10.3390/cancers15072105.

38. Ullah F, Dima D, Omar N, Ogbue O, Ahmed S. Advances in the treatment of Hodgkin lymphoma: Current and future approaches. Front Oncol. 2023 Mar 3;13:1067289. doi: 10.3389/fonc.2023.1067289.

39. Gurnari C, Gagelmann N, Badbaran A, Awada H, Dima D, Pagliuca S, D'Aveni-Piney M, Attardi E, Voso MT, Cerretti R, Wolschke C, Rubio MT, Maciejewski JP, Kröger N. Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M. Leukemia. 2023 Mar;37(3):717-719. doi: 10.1038/s41375-023-01820-4.

40. Lopetegui-Lia N, Dima D, Buchberger DS, Yalamanchali A, Osantowski B, Ondeck M, Lorenz RR, Prendes B, Ku J, Lamarre E, Scharpf J, Silver NL, Schwartzman L, Geiger JL, Woody NM, Campbell SR, Koyfman SA, Yilmaz E. Immunotherapy response in patients with cutaneous squamous cell carcinoma of head and neck with cranial nerve involvement. Head Neck. 2023 Jun 5. doi: 10.1002/hed.27419.

41. Markouli M, Ullah F, Omar N, Apostolopoulou A, Dhillon P, Diamantopoulos P, Dower J, Gurnari C, Ahmed S, Dima D. Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder. Cancers (Basel). 2022 Dec 1;14(23):5949. doi: 10.3390/cancers14235949.

42. Dima D, Jiang D, Singh DJ, Hasipek M, Shah HS, Ullah F, Khouri J, Maciejewski JP, Jha BK. Multiple Myeloma Therapy: Emerging Trends and Challenges. Cancers (Basel). 2022 Aug 23;14(17):4082. doi: 10.3390/cancers14174082.

43. J Dower, D Dima, M Lalla, AR Patel, RL Comenzo, C Varga. The use of PYP scan for evaluation of ATTR cardiac amyloidosis at a tertiary medical centre. May 2022. Br J Cardiol 2022;29:73–6doi:10.5837/bjc.2022.019

44. Dima D, Hu X, Dower J, Zhang D, Comenzo R, Varga C. Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience. Leuk Lymphoma. 2022 Jan 2:1-5. doi: 10.1080/10428194.2021.2018585.

45. Sideris GA, Vyllioti AT, Dima D, Chill M, Njuguna N. The Value of Web-Based Patient Education Materials on Transarterial Chemoembolization: Systematic Review. JMIR Cancer. 2021 May 7;7(2):e25357. doi: 10.2196/25357.

46. Zhang D, Dima D, Hu X, et al. NRAS Q61R-mutant mucosal melanoma with cardiac metastasis - a diagnostic challenge. MOJ Clin Med Case Rep. 2020;10(6):146‒150. DOI: 10.15406/mojcr.2020.10.00365

47. Dower J, Dima D, Sieker J, Pilichowska M, Varga C. Eculizumab-induced late erythroid maturation arrest: a case report. Br J Haematol. 2020 Oct;191(1):120-122. doi: 10.1111/bjh.16936.

48. Mao D, Hachem H, Chang H, Dima D, Dower J, Wismer M, Erban JK, Freund KM, Parsons SK. Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients. Breast Cancer Res Treat. 2020 Dec;184(3):665-674. doi: 10.1007/s10549-020-05892-z.

49. Dima D, Dower J, Comenzo RL, Varga C. Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy. Cancer Manag Res. 2020 Aug 26;12:7891-7903. doi: 10.2147/CMAR.S212526.

Scientific Press

1. Danai Dima and Pauline Funchain. To Adjuvant or Not to Adjuvant: The Current Conundrum of Adjuvant Immunotherapy for Patients With Melanoma. American Society of Oncology (ASCO) Daily News (Editorial, Expert Opinion). August 24, 2022

Poster/Oral Presentations as 1^st  Author in National/Regional Meetings

1. Dima D (Oral Presenter) Davis JA, Ahmed N, Sannareddy A, Shaikh H, Mahmoudjafari Z, Khouri J, Kaur G, Strouse C, Valent J, Anderson LD, Anwer F, Abdallah AO, & Hashmi H. Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma. American Society of Hematology Annual Meeting and Exposition December 2023, San Diego CA

2. Dima D (Poster Presenter), Davis JA, Rashid A, Rice M, DeJarnette S, Shune L, Khouri J, Raza S, McGuirk JP, Anwer F, Ahmed N, Abdallah AO, & Hashmi H. Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease. American Society of Hematology Annual Meeting and Exposition December 2023, San Diego CA

3. Dima D (Poster Presenter), Rashid A, Davis JA, Awada H, Abdallah AO, Li H, DeJarnette S, Shune L, Khouri J, Hashmi H, McGuirk JP, Anwer F & Ahmed N. Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study. American Society of Hematology Annual Meeting and Exposition December 2023, San Diego CA

4. Dima D (Poster Presenter), Sannareddy A, Ahmed N, Davis JA, Shaikh H, Mahmoudjafari Z, Duco M, Khouri J, Kaur G, Lochner J, Anwer F, Afrough A, Valent J, Hashmi H, & Abdallah AO. Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study. American Society of Hematology Annual Meeting and Exposition December 2023, San Diego CA

5. Dima D (Poster Presenter), Ullah F, Unlu S, Basali D, Khan M, Khan AS, Jia X, Jaberi-Douraki M, Faiman BM, Mazzoni S, Williams LS, Samaras CJ, Valent J, Anwer F, Khouri J, & Raza S. Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12-Year Experience of a Large Academic Center. American Society of Hematology Annual Meeting and Exposition December 2023, San Diego CA

6. Danai Dima (Poster Presenter), Hasipek M, Singh DJ, Jiang D, Tiwari AD, Grabowski D, Parker Y, Lindner DJ, Zhao J, Shain KH, Khouri J, Maciejewski JP, & Jha BK. Heightened Endoplasmic-Reticulum Stress Is a Targetable Vulnerability of Malignant Plasma Cells in Multiple Myeloma. American Society of Hematology Annual Meeting and Exposition December 2022, New Orleans LA

7. Danai Dima (Poster Presenter), Ullah F, Omar N, Gurnari C, Dhillon P, Visconte V, Jha BK, & Maciejewski, JP. Clinical and Mechanistic Relationship of T-Cell Large Granular Lymphocytic Leukemia (TLGL) and monoclonal Gammopathy of Undetermined Significance (MGUS). American Society of Hematology Annual Meeting and Exposition, December 2022, New Orleans LA

8. Danai Dima (Poster Presenter), Hasipek M, Singh DJ, Jiang D, Tiwari AD, Grabowski D, Parker Y, Lindner DJ, Zhao J, Shain KH, Khouri J, Maciejewski JP, & Jha BK. Heightened Endoplasmic-Reticulum Stress is a Targetable Vulnerability of Malignant Plasma Cells in Multiple Myeloma. The Case Comprehensive Cancer Center Annual Scientific Retreat, July 2022, Cleveland OH

9. Danai Dima (Oral Presenter), Lopetegui NL, Osantowski B, Song JM, Kennedy LB, & Funchain P. Suspected Checkpoint Inhibitor-Related Cholecystitis in Patients with Metastatic Melanoma. Cleveland Clinic Management of Checkpoint Inhibitor Related Toxicity Annual Conference, March 2022, Cleveland OH

10. Danai Dima (Poster Presenter) & Niyoti Reddy. Solving a Mystery Case of Hypoglycemia. New England & Mountain West Regional Meeting, November 2020 (Virtual)

11. Moderator: 21^st Annual Tufts Clinical and Translation Science Symposium, May 2019, Boston MA

Google Scholar Link:

https://tinyurl.com/2s4b2m7c